Constellation: More epigenetic stars

Researchers have been working in the field of epigenetics for a long time, but so far few targets have been identified. And only two classes of targets - histone deacetylases and DNA methyltransferases - have yielded approved drugs.

Constellation Pharmaceuticals Inc. is hoping to take advantage of recent advances in biochemistry that it believes will make epigenetic targets more accessible. The company hopes to discover cancer compounds targeting two other classes: histone methyltransferases and histone demethylases...